Andrew Allen, Gritstone CEO (Gritstone via website)
August 17, 2021 07:29 AM EDTUpdated 10:35 AM
Coronavirus

Covid-19 roundup: CEPI in­jects $20.6M in­to Grit­stone's push for a next-gen vac­cine; Quali­gen shelves its Covid-19 can­di­date af­ter a failed IND

Nicole DeFeudis

Editor

As the Delta vari­ant dri­ves a glob­al surge in Covid-19 cas­es, the Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions (CEPI) is in­vest­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times